Press release
Parkinson's Disease Pipeline Analysis, 2025 by DelveInsight | Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Inc, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech,
Parkinson's disease pipeline
DelveInsight reports that the Parkinson's Disease pipeline includes over 130 key companies actively developing more than 150 therapeutic candidates.
Parkinson's Disease Overview:
Parkinson's disease (PD) is a chronic, progressive neurological disorder that primarily affects movement. It arises from the gradual loss of dopamine-producing neurons in the substantia nigra, a brain region critical for motor control. Although PD most commonly develops in individuals over 60, it can occasionally occur earlier. It is the second most common neurodegenerative disease after Alzheimer's, and its progression varies widely among patients, making prediction and management challenging.
The primary motor symptoms of PD include tremors, slowed movement (bradykinesia), muscle stiffness (rigidity), and postural instability. Tremors usually begin in a single limb, often the hand or fingers, and are most noticeable at rest. Bradykinesia can significantly interfere with daily activities by slowing voluntary movements. Muscle rigidity leads to stiffness and limited motion, while postural instability increases the risk of falls. PD also presents with non-motor symptoms, including sleep disturbances, depression, anxiety, cognitive impairment, and autonomic nervous system dysfunction.
Download our report @ https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Parkinson's Disease Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Parkinson's Disease Therapeutics Market.
Key Takeaways from the Parkinson's Disease Pipeline Report
DelveInsight's Parkinson's Disease (PD) pipeline report highlights a vibrant landscape, with over 130 companies actively developing more than 150 therapeutic candidates.
Key regulatory updates include:
*
February 2025: The FDA approved Medtronic's BrainSense Adaptive Deep Brain Stimulation (aDBS) system, which adjusts stimulation in real-time based on brain signals, offering more personalized symptom management compared to traditional continuous DBS devices.
*
February 4, 2025: The FDA approved Onapgo (apomorphine hydrochloride), a continuous subcutaneous infusion therapy for PD patients experiencing significant "off" episodes, when standard medications are less effective.
*
October 2024: The FDA approved Vyalev (foscarbidopa and foslevodopa), the first 24-hour subcutaneous continuous levodopa infusion for adults with advanced PD and motor fluctuations, providing consistent dopamine delivery for steady symptom control.
Leading companies developing PD therapies include Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, Minerva Neurosciences, Mitsubishi Tanabe Pharma Corporation, Tetraneuron, Kallyope, BlueRock Therapeutics LP, Neuraly, Peptron, Yuhan Corporation, Genentech, Kissei Pharmaceutical, Asklepios BioPharmaceutical, Alkahest, Modag, Intra-Cellular Therapies, Living Cell Technologies, MedImmune, and others.
Notable PD pipeline therapies in various stages of development include Buntanetap, Tavapadon, Prasinezumab, Risvodetinib, GT 02287, among several additional candidates.
Parkinson's Disease Pipeline Analysis
The Parkinson's Disease pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Parkinson's Disease Market.
*
Categorizes Parkinson's Disease therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Parkinson's Disease drugs under development based on:
*
Stage of development
*
Parkinson's Disease Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Parkinson's Disease Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Parkinson's Disease Licensing agreements
*
Funding and investment activities supporting future Parkinson's Disease market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Parkinson's Disease Emerging Drugs
*
Buntanetap: Annovis Bio
*
Tavapadon: Cerevel Therapeutics
*
Prasinezumab: Roche
*
Risvodetinib: Inhibikase Therapeutics, Inc
*
GT 02287: Gain Therapeutics
*
NNI 362: Neuronascent
Parkinson's Disease Companies
More than 130 leading companies are actively developing therapies for Parkinson's disease, with Annovis Bio advancing a drug candidate to the most advanced stage-Phase III clinical trials.
DelveInsight's report covers around 150+ products under different phases of Parkinson's Disease clinical trials like
*
Parkinson's Disease Late stage Therapies (Phase III)
*
Parkinson's Disease Mid-stage Therapies (Phase II)
*
Parkinson's Disease Early-stage Therapies (Phase I)
*
Parkinson's Disease Pre-clinical and Parkinson's Disease Discovery stage Therapies
*
Parkinson's Disease Discontinued & Inactive Therapies
Parkinson's Disease pipeline report provides the Parkinson's Disease therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Parkinson's Disease Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Parkinson's Disease Therapies and Key Parkinson's Disease Companies: Parkinson's Disease Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Parkinson's Disease Pipeline Therapeutic Assessment
- Parkinson's Disease Assessment by Product Type
- Parkinson's Disease By Stage
- Parkinson's Disease Assessment by Route of Administration
- Parkinson's Disease Assessment by Molecule Type
Download Parkinson's Disease Sample report to know in detail about the Parkinson's Disease treatment market @ Parkinson's Disease Therapeutic Assessment [https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Parkinson's Disease Current Treatment Patterns
4. Parkinson's Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Parkinson's Disease Late-Stage Products (Phase-III)
7. Parkinson's Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Parkinson's Disease Discontinued Products
13. Parkinson's Disease Product Profiles
14. Parkinson's Disease Key Companies
15. Parkinson's Disease Key Products
16. Dormant and Discontinued Products
17. Parkinson's Disease Unmet Needs
18. Parkinson's Disease Future Perspectives
19. Parkinson's Disease Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Parkinson's Disease Pipeline Reports Offerings [https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=parkinsons-disease-pipeline-analysis-2025-by-delveinsight-annovis-bio-cerevel-therapeutics-roche-inhibikase-therapeutics-inc-gain-therapeutics-neuronascent-anew-medical-longevity-biotech]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease Pipeline Analysis, 2025 by DelveInsight | Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Inc, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, here
News-ID: 4165690 • Views: …
More Releases from ABNewswire
Why Outside Investors Are Suddenly Interested in Law Firms That Used to Turn The …
Spartanburg, United States - 18 August, 2026 - For most of the last century, practicing law in the United States came with a strict rule that had almost no exceptions, only licensed attorneys could own a stake in a law firm. Investors, corporations, and anyone without a bar license were kept firmly on the outside, regardless of how much capital they had to offer or how interested they were in…
UCM Upholstery Cleaning Sees Growing Interest in Family-Friendly Green Furniture …
BALTIMORE - August 18, 2026 - A sofa can become the busiest piece of furniture in a home. Children snack on the cushions, pets curl up in the corners, and family members spend hours there each week. That daily use leaves upholstery exposed to dust, pet hair, food spills, body oils, and odors. UCM Upholstery Cleaning Baltimore is seeing growing interest in eco-friendly upholstery cleaning for homes where furniture receives…
August 20 Officially Declared "National Day of Gratitude," Honoring the Life and …
National recognition transforms a young man's legacy into an annual call for Americans to practice gratitude, kindness, and compassion
Image: https://www.abnewswire.com/upload/2026/08/e3cea0329d7541a7cf1699b2bef0edf9.jpg
AUSTIN, Texas - August 18, 2026 - National Day Archives has officially declared August 20 as the "National Day of Gratitude," establishing an annual observance dedicated to inspiring people across America to embrace gratitude, kindness, and compassion in their everyday lives.
The date carries profound significance. August 20 is the birthday of…
Family-Run 4G3D Creations Brings Fantasy and Magic to Life Through Custom 3D Pri …
4G3D Creations, a family-operated design and 3D printing studio, is earning a devoted following among fantasy enthusiasts and tabletop gamers with its enchanting range of glowing sculptures, gaming gear, and custom creations. Every product is conceived, designed, and printed entirely in-house, offering customers a personal touch that mass-produced alternatives simply cannot match.
BUFFALO, New York - August 18, 2026 - In a marketplace increasingly dominated by faceless manufacturers and overseas fulfillment…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
QualitySolicitors Parkinson Wright invest in the future
QualitySolicitors Parkinson Wright has selected Liberate from Linetime as its business-wide legal services software platform. The Worcestershire based practice, with over 100 staff, operate from 4 offices and have a highly regarded reputation for their services including residential property, private client, family, dispute resolution and commercial. The firm also has its own estate agency.
The firm recognised that to continue delivering high quality services to its clients it needed to provide…
